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ABSTRACT 
 
Thrombocytosis has been suggested to be a poor prognostic indicator in malignancies. Platelet granules contain a 
variety of growth factors which are secreted immediately after platelet activation which have been implicated in 
tumor progression and in the development of metastasis. Studies have shown that thrombocytosis is associated with 
a poor prognosis in various gyanecological and non gynaecological malignancies. This independent prognostic 
factor may provide a simple approach to improved risk stratification of patients in future clinical trials. 
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Introduction 
 
The association of thrombocytosis with malignancies 
has been known for more than 100 years [1].Studies 
have shown that thrombocytosis is associated with a 
poor prognosis in various gyanecological and non-
gyanecological malignancies[2-8]. Recently, 
thrombocytosis was reported in patients with lung 
cancer,[2,3[colon,[3] renal cell carcinomas,[4]breast 
cancer[5] and gynecological malignancies such as 
cervical cancer[6]ovarian cancer[7] and vulvar 
cancer[8].We conducted MEDLINE and PUBMED 
search of the literature on the prognostic impact of 
thrombocytosis in breast cancer using the search term 
thrombocytosis in breast cancer, thrombocytosis , 
platelet count. References of all publication were also 
searched. We tried to analyse the impact of 
thrombocytosis on the prognosis of breast cancer, 
relationship between platelet count and the breast 
cancer. Thrombocytosis is defined as an elevated 
platelet counts above 4.5x10
9
/l. Difficulties in 
interpreting abnormalities of the platelet count in 
malignancy arise because several conditions may 
influence the platelet levels. Malignancy is often 
accompanied by disseminated intravascular 
coagulation and bone marrow involvement, which tend 
to lower peripheral platelet counts. Treatment with  
_______________________________ 
*Correspondence  
Dr. Deepti Sharma 
Assistant Professor, Radiation Oncology,VMMC and 
Safdarjung Hospital, New Delhi, India 
E Mail: drdeeptisharma16@gmail.com 
chemotherapy and radiation therapy also decreases 
platelet count. Platelets or thrombocytes are small, 
irregularly-shaped anuclear cell fragments which are 
derived from fragmentation of precursor 
megakaryocytes.[9] Megakaryocyte and platelet 
production is regulated by Thrombopoetin, a hormone 
usually produced by the liver and kidneys.[10, 11]
 
Old 
platelets are destroyed by phagocytosis in the spleen 
and by Kupffer cells in the liver. A reserve of platelets 
is stored in the spleen and is released when needed by 
sympathetically-induced splenic contraction. 
 
Interaction of tumor cells and platelet 
 
The steps involved in metastasis of tumor are entry of 
tumor cells in the bloodstream, an intravascular phase 
followed by extravasation of tumor cells from the 
capillaries resulting in metastasis at the distant site. 
Platelets participate in tumor progression by 
contributing to the metastatic cascade, protecting tumor 
cells from immune surveillance, regulating tumor cell 
invasion, and angiogenesis[12-16]Thrombin is being 
generated either by direct contact with platelets or 
indirectly by stimulating tissue factor-mediated 
activation of the coagulation system[17] In a study by 
Egan et al,  the ovarian cancer induced platelet 
activation is mediated by adenosine 59-diphosphate 
released from tumor cells and can be blocked by 
adenosine 59-diphosphate receptor (P2Y12 and P2Y1) 
antagonists[18]. Certain studies have also shown that 
tumor cells could lead to secretion of dense granules 
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containing adenine nucleotides via the platelet Fcg 
receptor IIa[19].Platelet activation by tumors 
throughout all phases of the metastatic cascade leads to 
the release of platelet-derived factors stored in their 
granules leading to inflammatory, proliferative, and 
proangiogenic activities of platelets to promote tumor 
growth, tissue invasion, and metastasis[20,21].The 
platelets secrete thrombospondin-1 which facilitates the 
adhesion of tumor cells to the endothelium, promotes 
extravasations in the metastatic cascade[22,23]. The 
thrombospondin levels have found to be elevated in 
women with gynecologic malignancies. Once the 
tumor cells have exited circulation, factors derived 
from activated platelets are able to induce 
neoangiogenesis thereby enabling growth at the 
metastatic site[24]. 
Reactive or secondary thrombocytosis associated with 
malignancies has been established since the early 
1870s, with an incidence of 10-57%.[23].Possible 
mechanisms include an overproduction of 
cytokines/growth factors stimulating megakaryocytes 
and their precursors. Serum IL-6 is increased in most 
patients with reactive thrombocytosis, and elevation of 
this cytokine has been detected in a significant number 
of patients with cancer. Bone marrow endothelial cells, 
kidney, and spleen are capable of Thrombopoetin 
(TPO) production. TPO is produced and released into 
the circulation at a constant rate by the liver.[10] 
Normal physiology of platelet production involves the 
clearance of TPO by high affinity TPO receptors on 
platelets and formation of a steady TPO concentration, 
thereby providing a basal stimulation of bone marrow 
megakaryocytes and normal rate of platelet production. 
However, in secondary thrombocytosis that can occur 
with malignancies, there can be up-regulation of TPO 
production by the liver, causing enhanced 
thrombopoiesis. Plasma TPO levels have also been 
shown to correlate with IL-6[25]. Platelets have 
capabilities to enhance sequestration, adherence, and 
penetration of malignant cells through the endothelial 
wall [22].They may also prevent the immune system 
from clearing tumor cells from the circulatory system. 
Thrombospondin, a platelet-secreted protein, is 
increased in patients with cancer, specifically in 
patients with metastasis, and may promote the 
adherence of tumor cells to the endothelial barrier, thus 
enhancing their escape from immune surveillance. 
Tumor growth is dependent on formation of new blood 
vessels from preexisting capillaries (i.e., 
angiogenesis)[26].
 
Tumor angiogenesis is dependent 
not only on endothelial cells and cancer cells but also 
on platelet-endothelium interactions. Platelets adhere to 
the tumor-related endothelium and release high 
concentrations of VEGF, which is a potent stimulator 
of angiogenesis. Platelet granules contain a variety of 
factors such as VEGF, basic fibroblast growth factor 
(bFGF), platelet-derived growth factor (PDGF), 
transforming growth factor beta (TGF- ), IL-6, 
thrombin, and fibrinogen [27]. These modulators are 
secreted immediately after platelet activation, and 
many have been implicated in various steps of tumor 
progression and in the development of metastasis.  As 
one of the most significant proangiogenic cytokines, 
bFGF contributes to migration, proliferation, and 
differentiation of endothelial cells, and regulation of 
the expression of proangiogenic molecules. PDGF 
induces angiogenesis by means of stimulation of VEGF 
expression in tumor endothelial cells and by recruiting 
pericytes to new blood vessels. TGF-  has an active 
role in platelet aggregation and regulation of 
megakaryocyte activity[28].
 
This cytokine also 
regulates the activity of the VEGF system and 
enhances endothelial cell survival[29]. 
 
Table 1: summaries of studies of thrombocytosis in breast cancers 
 
Cases (N) Stage  Prevalence % Thrombocytosis vs Normal platelet counts Ref  
165 Metastatic 18.2% OS  P=0.038 and PFS, p= 0.008 30 
4300 Non metastatic 3.7% OS P=0.0054  and PFS, p=0.0199 5 
27 All stages 0.78% No impact on OS and DFS 31 
 
 
 
Thrombocytosis in breast cancer 
 
Taucher et al studied the impact of pretreatment 
thrombocytosis on survival in primary breast cancer. 
They performed a retrospective, multivariate analysis 
of 4,300 patients with early-stage breast cancer. 
Pretreatment thrombocytosis was observed in 161 
patients (3.7%). Patients with thrombocytosis were 
usually associated with younger age group (p=0.014), 
nodal positivity (p=0.035) and higher grade (p=0.005). 
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Estimated median OS, breast cancer-related survival 
and DFS for patients with versus those without 
thrombocytosis was 71.0 versus 99.5, 72.0 versus 
100.9, and 80.4 versus 88.4 months, respectively (p = 
0.0054, p = 0.0095, p = 0.0199). A multiple Cox 
regression model including tumor and nodal status, 
grading, age, hormone receptor status and pretreatment 
thrombocytosis identified pretreatment thrombocytosis 
as an independent predictive factor for OS (p = 0.0064) 
and breast cancer-related survival (p = 0.0162). Thus 
elevated platelet counts at time of diagnosis were 
associated with poor prognosis in breast cancer [5].
 
Stravodimou A et al in the study of 165 metastatic 
breast cancer showed that thrombocytosis is prevalent 
in 18.2% of the patients. The study concluded that a 
statistically significant difference in overall and 
progression free survival favouring the normal platelets 
group (Log Rank test 𝑃 = 0.038 and 0.008, resp.). The 
multivariate Cox regression analysis showed that 
higher grade, ER/PR negativity, the presence of 
thrombocytosis were statistically and significantly 
associated with reduced progression free survival and 
Overall survival. It has been showed from the studies 
that pretreatment thrombocytosis is associated with 
reduced OS and DFS. Thrombocytosis is also 
associated with higher grade, young age, ER/PR 
negative tumor and more advanced cases. Further study 
is required to confirm these results and especially to 
test whether thrombocytosis can serve as a predictive 
marker of specific treatments. As it is already known 
that platelet contains VEGF resulting in an irreversible 
cascade and resulting in tumor progression. The role of 
anti-VEGF in the management of breast cancer with 
thrombocytosis is still unknown and further studies can 
be done to evaluate its use.   
 
Conclusion 
 
 The prevalence of thrombocytosis associated with 
breast cancer portrays a worse survival, independent of 
other clinical or biochemical factors. With further 
studies, this single independent prognostic factor may 
provide a simple approach to improved risk 
stratification of patients in future clinical trial 
protocols. 
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